8-K/A: VSee Health Secures Nasdaq Listing with $9.5M Equity Boost

VSee Health, Inc. announced an amendment to its 8-K filing, detailing transactions that boosted its pro forma stockholders' equity to $9.5 million, ensuring compliance with Nasdaq listing requirements.

Summary

• VSee Health, Inc. filed an amendment to its 8-K, updating its pro forma balance sheet as of December 1, 2025.
• The company's pro forma total stockholders' equity as of December 1, 2025, is $9.5 million, a significant improvement from a deficit of $18,488 as of December 31, 2024.
• This increase brings the company into compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000, thereby resolving a delisting threat.
• Compliance was achieved through a series of transactions including the exercise of warrants, conversion of convertible notes and preferred shares into common stock, and exchange of payables for common and preferred shares.
• The transactions included the conversion of over $8.2 million in principal and interest from various convertible notes and promissory notes into common stock.
• A warrant exchange agreement resulted in the issuance of 1,547,568 common shares in exchange for 1,596,435 warrants.
• A private placement (PIPE) on November 25, 2025, raised approximately $6 million in gross proceeds by selling 9,836,065 shares (or pre-funded warrants) and warrants to purchase 19,672,130 shares at $0.61 per unit.
• Pro forma cash increased significantly to $7,492,831 as of December 1, 2025, from $326,115 as of December 31, 2024.
• Pro forma total liabilities decreased to $16,204,452 as of December 1, 2025, from $20,010,976 as of December 31, 2024.
• Common stock shares outstanding increased to 39,440,816 pro forma as of December 1, 2025, from 16,297,190 as of December 31, 2024.

Sentiment

Score: 7

Explanation: The company successfully addressed a critical delisting issue by significantly improving its balance sheet through debt-to-equity conversions and a capital raise. While this is a strong positive, the substantial dilution and the need for such drastic measures indicate underlying financial challenges that required significant restructuring.

Positives

• Achieved compliance with Nasdaq's minimum stockholders' equity requirement, preventing delisting.
• Significantly improved financial position, moving from a stockholders' deficit to a positive equity of $9.5 million.
• Reduced total liabilities by approximately $3.8 million on a pro forma basis.
• Increased cash reserves substantially to $7.49 million through warrant exercises and a private placement.
• Successfully converted a significant amount of debt (over $8.2 million principal and interest) into equity, strengthening the balance sheet.
• Secured $6 million in gross proceeds from a private placement, providing additional capital.

Negatives

• Significant dilution of existing shareholders due to the issuance of millions of new common shares from debt conversions, warrant exchanges, and the private placement.
• The company was previously in non-compliance with Nasdaq listing rules, indicating past financial challenges.
• The private placement was conducted at $0.61 per share, which could be below market price, potentially signaling a need for urgent capital or a low valuation.
• The company agreed to a 10-day lock-up period following the warrant exchange, restricting certain capital market activities.

Risks

• Delisting Risk: The company was previously at risk of delisting from Nasdaq due to non-compliance with the Equity Rule. While compliance has been achieved pro forma, ongoing monitoring is required to maintain this status.
• Shareholder Dilution: The extensive issuance of common stock through debt conversions, warrant exercises, and the private placement significantly dilutes the ownership percentage of existing shareholders.
• Future Compliance: Maintaining compliance with Nasdaq listing rules, including the Equity Rule, will require sustained financial performance and management.
• Market Price Volatility: The issuance of a large number of shares at a specific price ($0.61 in the PIPE) could impact the market price of the common stock.

Future Outlook

The company has successfully executed a compliance plan to meet Nasdaq's Equity Rule, indicating a stabilized financial foundation for continued listing. The capital raised and debt converted are expected to support ongoing operations and strategic initiatives, though no specific forward guidance on future performance or revenue is provided.

Management Comments

• "The Company believes that it has demonstrated compliance with the Equity Rule on a pro forma basis following closing of the following the exercise of certain outstanding warrants, the conversion into common stock of multiple outstanding convertible notes and preferred shares, and the exchange of certain outstanding payables of the Company into common stock and preferred shares."

Industry Context

This filing reflects a common challenge for smaller public companies, particularly in the healthcare technology sector, to maintain compliance with stringent exchange listing requirements. The strategy of converting debt to equity and raising capital through private placements is a typical approach to address balance sheet deficiencies and avoid delisting, allowing the company to continue accessing public markets for funding and visibility.

Comparison to Industry Standards

• NA

Related Party Transactions

• The Quantum convertible note, related party at fair value, was converted.
• Loan payable, related party, is listed on the balance sheet.
• Due from related party is listed on the balance sheet.
• Due to related party is listed on the balance sheet.

Stakeholder Impact

• Shareholders: Existing shareholders experienced significant dilution due to the issuance of millions of new shares. However, the prevention of delisting preserves the liquidity and tradability of their investment on Nasdaq.
• Creditors: Convertible noteholders and other creditors who converted their debt into equity have become shareholders, reducing the company's debt burden.
• Nasdaq: The company's actions demonstrate compliance with Nasdaq's listing rules, maintaining the integrity of the market.

Next Steps

• Maintain compliance with Nasdaq listing rules.
• Integrate the newly raised capital and restructured balance sheet into ongoing operations and strategic plans.

Key Dates

Recommendation

The company successfully navigated a critical delisting threat by significantly improving its balance sheet and raising capital. This removes a major overhang and provides a more stable foundation. However, the substantial shareholder dilution from the various equity issuances and the low price of the PIPE offering ($0.61) suggest that the company faced significant financial distress. While the immediate crisis is averted, the long-term value creation and operational performance need to be closely monitored before a more bullish stance can be taken. The stock is a 'hold' as the immediate risk is mitigated, but future growth and profitability are still uncertain given the past financial challenges and the cost of this restructuring.

Keywords

VSee Health, Nasdaq Compliance, Stockholders Equity, 8-K/A, Convertible Notes, Warrants, Private Placement, PIPE, Equity Rule, Delisting, Financial Health, Balance Sheet, VSEE, VSEEW